GLP-1 drugs work for weight loss, study finds

The Food and Drug Administration expanded the approval of weight ... The approval supports evidence that GLP-1 drugs ...
In a rare move, the FDA recommended a minimum of 5% weight-loss for drug developers seeking to establish the efficacy of ...
Tirzepatide is the active ingredient in Zepbound, the FDA approved prescription medicine for Obstructive Sleep Apnea.
The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...
The FDA approval for sleep apnea is ... That equates to 45 to 50 pounds of weight loss, on average, over a year, Lilly said. Patients on the drug also saw reductions in blood pressure and ...
On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a declaratory order determining that the shortage of diabetes and ...
Glucagon-like peptide-1 receptor agonist drugs may reduce the risk of surgical complications in diabetic patients, according to a large new study. The study showed diabetic patients taking GLP-1 drugs ...
For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...